^
Association details:
| Biomarker: | FLT3-ITD mutation + IDH1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug Class: | IDH1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
Published date:
10/29/2020
Excerpt:
The authors reviewed cases of patients with FLT3-internal tandem duplication (FLT3-ITD)-mutated AML with concurrent IDH mutations...CCT with IDHIs was given in 2 frontline patients and both achieved a CR….Fewer patients with double-mutated disease received CCT or LIT with IDH1/2 inhibitor in the frontline setting; however, high response rates also were noted with this approach.
DOI:
10.1002/cncr.33293
